Kush Parmar, M.D., Ph.D.

Dr. Kush M. Parmar is a Managing Partner at 5AM Ventures. Dr. Parmar serves as a Director on the Boards of Arvinas, Audentes, Homology and scPharmaceuticals. He previously served as Acting VP of Strategy and Corporate Development at Novira (acquired by J&J) and was Board Observer for Envoy (acquired by Takeda), Achaogen (NASDAQ: AKAO) and Pulmatrix (NASDAQ: PULM). He serves on the Scientific Advisory Council of Princeton University's Department of Molecular Biology and for the Grace Wilsey Foundation and is a Fellow of the Society of Kauffman Fellows. Before joining 5AM, Dr. Parmar was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow at Harvard Medical School and completed clinical clerkships at the Massachusetts General & Brigham and Women's Hospitals. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.

Steve Gillis, Ph.D.

Dr. Steven Gillis is a Managing Director with ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH's biotechnology portfolio companies. Dr. Gillis was a founder and director of Corixa Corp. and served as CEO from its inception and as its Chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp., the most successful venture-funded biotech company in the state of Washington. From 1981 until his departure in 1994, he served as Immunex's Director of Research and Development, Chief Scientific Officer, and as CEO of Immunex's R&D subsidiary. Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein), as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis is a director of Shire Pharmaceuticals, Allozyne, Pulmatrix, Codiak Biosciences, Faraday Pharmaceuticals, Just Biotherapeutics, VLST, and Accelerator. He serves as director and Chairman of VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines, and PhaseRx. He received a B.A. from Williams College and a Ph.D. from Dartmouth College.

Richard Gregory, Ph.D.

Dr. Richard Gregory is the Executive Vice President and Chief Scientific Officer of ImmunoGen. He joined ImmunoGen in 2015 bringing over 25 years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme. His group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and to determine the molecular defect caused by the most common mutation in CFTR. In 1990 Dr. Gregory founded the Gene Therapy program at Genzyme and was Vice President for Gene Therapy until 2003. In 2003, he was appointed Senior Vice President and Head of Research at Genzyme, with responsibility for early research – from discovery to development – for all Genzyme therapeutic areas, including rare diseases, oncology, renal and immunology. Following Sanofi's acquisition of Genzyme in 2011, Dr. Gregory was appointed Head of the Sanofi-Genzyme R&D Center and in that capacity was responsible for Genzyme R&D from discovery through regulatory approval. He received his doctorate in biochemistry from the University of Massachusetts at Amherst, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology.

Arthur Tzianabos, Ph.D., President and CEO

Dr. Tzianabos is President and CEO of Homology Medicines. He brings 25 years of experience in the biotechnology industry leading teams in the discovery, development, clinical translation and commercialization of new treatments for rare diseases. During his nine-year tenure at Shire, he played an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire's product pipeline. Dr. Tzianabos joins Homology Medicines from OvaScience where he served as President and CSO and was responsible for translating breakthrough science into new treatments, which included the commercial launch of the company's first product. Earlier in his career, Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women's Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. He has published more than 80 scientific papers, reviews, book chapters, and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.